The technology is based on the pharmaceutical modulation (not DDS) of existing and proven CNS drugs to generate a new efficacy/safety profile, enabling new IP, new indications, and premium pricing. This technology is versatile and adaptable to numerous classes of CNS drugs and indications.
Our approach benefits from rapid and lower cost development programs, enabling an accelerated time to market.
Our use of safety proven registered molecules ensures a low risk of late stage project failure.
Our technology and products are covered by a robust portfolio of patents
Theranexus’ products are fixed dose combinations between established and proven CNS drugs and off-patent, FDA/EMA registered and safety proven molecules.
Theranexus’ first product, THN102, composed of modafinil and THN02, is positioned to treat the residual sleepiness in narcoleptic patients (50% to 70% of narcoleptic patients). This is a first-in-class candidate combination, with a completed regulatory non-clinical phase and a proven safety in healthy subjects. It is currently under investigation in a clinical proof of concept in narcoleptic patients.
Find us: 86, rue de Paris 91400 Orsay France | 60, Avenue Rockefeller - Pépinière Laënnec - 69008 Lyon